Table of Contents
Overview
Definition of Cancer Research
Cancer research is a multidisciplinary field dedicated to understanding cancer's biology, prevention, diagnosis, and treatment. The history of cancer research reveals significant advancements, particularly in the 20th century, which marked a transformative period in the field. Prior to this era, cancer treatment was largely confined to individual physicians' practices, with limited understanding of the disease's incidence and variability across populations. However, World War II catalyzed a shift, leading to the establishment of medical research centers that began to uncover substantial international differences in cancer incidence, thereby laying the groundwork for more systematic research efforts.[1.1] Throughout the 20th century, the understanding of cancer evolved dramatically. Researchers made significant strides in identifying the causes of cancer and developing effective treatment modalities. This period saw the introduction of various preventive measures and therapeutic approaches, which have led to improved survival and cure rates for many cancer types.[3.1] The advancements in cancer research during this century have overshadowed previous centuries, highlighting the rapid progress made in understanding and combating this complex disease.[3.1] As cancer research continues to evolve, it remains an exciting and dynamic field, with ongoing discoveries that promise to further enhance our understanding and treatment of cancer. The future of cancer research is characterized by a commitment to innovation and a deeper exploration of the biological mechanisms underlying cancer, which is essential for developing more effective therapies and improving patient outcomes.[4.1]Importance of Cancer Research
Cancer research plays a crucial role in advancing our understanding of cancer and improving treatment outcomes. Over the past decade, significant breakthroughs have emerged, reshaping the landscape of cancer treatment and prevention. For instance, in October 2023, a potentially groundbreaking mRNA vaccine for pancreatic cancer entered a Phase 2 clinical trial, which is tailored for each of the approximately 260 enrolled patients, aiming to prevent the disease.[5.1] This development exemplifies the shift towards personalized medicine, where treatments are customized to individual patient profiles. Moreover, advancements in data analysis from gene sequencing have enabled researchers to identify mutations in lung cancer genes, leading to new treatment options when existing precision drugs fail.[6.1] This reflects a broader trend in cancer research, where the complexity of cancer is being addressed through innovative strategies, such as the identification of tumor-specific neo-antigens and the development of personalized cancer vaccines.[8.1] These efforts are supported by funding that not only promotes exceptional research but also ensures that scientists receive the necessary training to become leaders in cancer immunotherapy. The evolution of cancer treatment has also seen a reduction in the need for radical surgeries, with new organ-sparing therapies enhancing survivorship care and support for patients.[9.1] This shift is indicative of a new era in cancer treatment, where the focus is on improving patient quality of life alongside survival rates. For example, the approval of oncolytic viruses like T-VEC and Delytact for melanoma and malignant glioma, respectively, highlights the resurgence of innovative treatment modalities.[11.1] Additionally, the introduction of targeted therapies, such as Sotorasib for specific KRAS gene mutations, underscores the importance of precision medicine in managing aggressive cancers.[11.1] Furthermore, clinical trials continue to play a vital role in testing new treatments, with researchers exploring the impact of interventions on gut microbiome balance and their potential to enhance treatment efficacy.[12.1] These studies not only contribute to the scientific understanding of cancer but also translate into tangible benefits for patients, as evidenced by significant improvements in event-free survival rates among those receiving novel therapies.History
Milestones in Cancer Research Development
The history of cancer research has been marked by significant milestones that have transformed the understanding and treatment of the disease. Initially, cancer treatment was limited to individual physicians' practices, with little collaboration or systematic research. This changed dramatically during World War II, when medical research centers began to identify substantial international differences in cancer incidence, paving the way for more organized research efforts.[1.1] The 20th century was particularly pivotal, as it witnessed groundbreaking advancements in cancer treatment methodologies. For instance, the mid-1970s saw the publication of two landmark studies on adjuvant chemotherapy for breast cancer, which demonstrated the effectiveness of both single-drug and combination therapies. By 1991, these advancements, along with improved diagnostic tools and clinical trials, contributed to a significant decline in breast cancer mortality rates.[47.1] Furthermore, the introduction of targeted therapies, such as imatinib for chronic myeloid leukemia in 2006, marked a paradigmatic shift in cancer treatment, emphasizing the importance of targeting specific molecular abnormalities.[47.1] The approval of innovative therapies in recent years, such as T-VEC in 2015 and Delytact in 2021, has underscored the resurgence of oncolytic viruses as viable cancer treatment options. Additionally, the 2020s have seen the FDA approve Sotorasib, the first small molecule inhibitor targeting specific KRAS gene mutations, reflecting the ongoing evolution of cancer care.[48.1] The National Comprehensive Cancer Network (NCCN) guidelines in 2021 further highlighted the role of immunotherapy and anti-angiogenic therapy in managing hepatocellular carcinoma, illustrating the continuous efforts to enhance patient outcomes.[48.1] The impact of these advancements is evident in the increasing survival rates for cancer patients. For example, the 5-year relative survival rate for patients diagnosed in the mid-1970s was 75%, which rose to 90% for those diagnosed between 2011 and 2017, largely due to advances in hormonal treatments and early detection through increased mammography screening.[49.1] In addition to scientific advancements, the role of patient advocacy has evolved significantly, influencing cancer research priorities and treatment advancements. Advocacy organizations have successfully raised public awareness about specific cancers, such as breast cancer, and have played critical roles in demanding improvements in treatment access and outcomes.[53.1] The structured engagement of patient advocates in clinical trial development, as demonstrated by initiatives at SWOG, has further integrated patient perspectives into the research process, enhancing the relevance and effectiveness of cancer studies.[52.1]Categories Of Cancer Research
Basic Research
Basic research, also referred to as laboratory research or bench science, represents the foundational level of cancer research. This type of research focuses on the study of cells, molecules, and genes that are fundamental to understanding cancer biology and its underlying mechanisms.[85.1] Basic researchers aim to uncover the biological processes that lead to cancer development, progression, and response to treatment, thereby providing essential insights that can inform further research and clinical applications.[84.1] The significance of basic research lies in its role as a precursor to more applied forms of research, such as clinical and translational research. By elucidating the fundamental aspects of cancer, basic research contributes to the development of innovative strategies for prevention, diagnosis, and treatment.[86.1] This interdisciplinary approach is crucial, as it mirrors the complexity of cancer itself and addresses the diverse challenges posed by various cancer types.[86.1]Translational Research
Translational research in cancer focuses on bridging the gap between laboratory discoveries and clinical applications, aiming to enhance patient care through effective therapies. This process typically begins with initial findings from cellular or animal models, which are subsequently evaluated through clinical trials to assess the safety and efficacy of new treatments. Collaboration between laboratory scientists and clinicians is essential to facilitate this transition from bench to bedside, ensuring that scientific advancements are effectively integrated into clinical practice.[87.1] The translation of basic cancer biology into effective clinical therapies presents significant challenges, including differences in research models, communication gaps, and limited funding. However, international collaborations have emerged as a transformative solution, integrating diverse resources and multidisciplinary expertise to enhance the translational process.[90.1] For instance, the Office of Translational Resources (OTR) plays a crucial role in assisting principal investigators in rapidly translating laboratory and clinical research into successful cancer therapeutics.[91.1] Recent advancements in cancer diagnostics and treatment modalities, such as immune checkpoint inhibitors and nanomedicines, exemplify the successful application of translational research. Immune checkpoint inhibitors have revolutionized the treatment of solid tumors, while nanomedicines offer targeted drug delivery systems that minimize side effects and improve patient outcomes.[93.1] Furthermore, innovative technologies like CRISPR gene editing have facilitated the development of new cancer models, enhancing the understanding of tumor biology and treatment responses.[94.1] Despite these advancements, the clinical impact of new diagnostic technologies, particularly in resource-limited settings, remains constrained by high costs and technical complexities.[88.1] Therefore, ongoing efforts are necessary to prioritize laboratory discoveries based on their potential impact on patient care, ensuring that the most promising findings are translated into effective clinical applications.[89.1]In this section:
Recent Advancements
Innovative Treatment Approaches
Recent advancements in cancer research have led to the development of innovative treatment approaches that significantly enhance patient care and outcomes. One of the most notable advancements is the use of antibody-drug conjugates (ADCs), which combine the specificity of monoclonal antibodies with the cytotoxic effects of chemotherapy drugs. This innovative class of therapies allows for targeted delivery of cytotoxic agents directly to cancer cells, thereby minimizing damage to healthy tissues and reducing systemic side effects associated with traditional chemotherapy.[137.1] By April 2023, a total of 13 different ADCs had received FDA approval for clinical use, marking a significant milestone in targeted cancer therapy.[137.1] In addition to ADCs, the TRACERx study has provided critical insights into tumor heterogeneity and its implications for targeted therapies. This project aims to define clonally dominant drivers of disease, which can inform treatment stratification for lung cancer patients.[128.1] The findings from TRACERx suggest that understanding the evolutionary dynamics of tumors can lead to more effective treatment strategies, particularly in addressing drug resistance and optimizing long-term care for cancer patients.[129.1] Moreover, 2023 saw the FDA approve several new treatments based on cutting-edge clinical trials, particularly for various cancer types including brain, colorectal, bladder, and endometrial cancers. Notably, pembrolizumab and durvalumab were approved for advanced endometrial cancer, demonstrating the ongoing evolution of treatment options available to patients.[144.1] The rapid translation of laboratory advancements into clinical practice underscores the transformative age of cancer care, as highlighted by experts in the field.[124.1]In this section:
Challenges In Cancer Research
Drug Resistance
The rise of drug resistance in cancer cells presents a formidable challenge in modern oncology, necessitating the exploration of innovative therapeutic strategies. Drug resistance is multifaceted, influenced by various factors including tumor burden, growth kinetics, tumor heterogeneity, and the microenvironment, which collectively hinder effective treatment outcomes.[165.1] One significant aspect of this challenge is the presence of cancer stem cells (CSCs), which are believed to contribute to treatment resistance through mechanisms such as drug efflux, enhanced DNA damage response, and activation of developmental pathways.[181.1] Current approaches to overcoming treatment resistance include combination therapies that co-administer drugs with different molecular mechanisms. This strategy aims to increase tumor cell killing while reducing the likelihood of resistance and minimizing overlapping toxicity.[167.1] Additionally, the identification of cancer cell dependencies through high-throughput synthetic lethality screens and integration of clinico-genomic data is being explored as a means to develop more effective therapeutic strategies.[166.1] Furthermore, the tumor microenvironment (TME) plays a critical role in drug resistance by preventing immune clearance of malignant cells and hindering drug absorption.[166.1] Understanding the underlying mechanisms of tumor evolution, which describes the presence of multiple divergent cancer cell subpopulations within the same tumor, is essential for developing effective interventions that can prevent the clonal selection of drug-tolerant cells.[166.1] Overall, addressing the complexities of drug resistance in cancer requires a comprehensive understanding of both biological mechanisms and innovative treatment paradigms.Access to Treatment
Access to effective cancer treatment remains a significant challenge, particularly in low- and middle-income countries (LMICs), where the majority of new cancer patients and deaths occur. LMICs account for 57% of new cancer cases and 65% of cancer-related deaths globally, highlighting the urgent need for comprehensive cancer services, including prevention, screening, diagnosis, and treatment.[192.1] However, profound health system challenges impede the implementation of these services, exacerbating disparities in cancer care.[192.1] Efforts to eliminate cancer health disparities are outlined in initiatives such as the National Cancer Plan, which aims to ensure equitable access to prevention, screening, treatment, and survivorship care.[193.1] The complexities of cancer disparities are influenced by both biological and societal factors that affect health outcomes.[193.1] Community engagement plays a crucial role in addressing these disparities by mobilizing resources and developing policies that respond to community needs.[195.1] Community-based organizations (CBOs) are increasingly recognized as vital in implementing interventions that improve access to cancer care, particularly in areas where traditional approaches have failed.[195.1] Moreover, the integration of artificial intelligence (AI) and machine learning (ML) in cancer research has the potential to enhance diagnostic and therapeutic precision. By analyzing vast datasets from genomics and proteomics, AI and ML can identify novel therapeutic targets, such as neoantigens, which are essential for developing personalized immunotherapies.[190.1] However, challenges related to data privacy, algorithm transparency, and clinical integration must be addressed to fully realize the benefits of these technologies in improving access to treatment.[189.1]Future Directions
Personalized Medicine
Personalized medicine in cancer research is increasingly recognized for its potential to tailor treatments based on individual patient characteristics, particularly through the integration of genomic and molecular profiling. Advances in cancer genomics, facilitated by next-generation sequencing technologies, have enabled the development of precision medicine approaches that guide the selection of the most appropriate treatments for individual cancer patients. However, the clinical application of these genomic insights remains limited to a small proportion of patients, highlighting the need for broader implementation strategies.[210.1] The integration of personalized medicine with immunotherapy presents unique challenges and opportunities. While tumor-associated biomarkers have been utilized to personalize kinase-targeted agents, similar approaches for immunotherapy have proven less robust. The identification of neoantigens—tumor-specific antigens that can elicit an immune response—remains a critical area of research. Accurate prediction of these neoantigens is essential for the development of personalized immunotherapies, including cancer vaccines and T-cell receptor-engineered therapies, which could significantly enhance treatment efficacy across a wider range of cancer patients.[210.1] Moreover, the landscape of cancer treatment is evolving with the emergence of various biological therapies, such as cancer vaccines, monoclonal antibodies, and adoptive cell transfer therapies. These modalities are increasingly being explored within the framework of personalized medicine, aiming to enhance specificity and effectiveness in targeting different cancer types.[211.1] Despite the promise of these therapies, challenges such as drug resistance and the need for high specificity in treatment protocols persist, necessitating ongoing research and innovation in the field.[211.1]Multidisciplinary Approaches
The integration of big data and artificial intelligence (AI) in cancer research is a pivotal aspect of future multidisciplinary approaches. Recent advancements in AI methodologies, coupled with enhanced computational hardware and access to extensive cancer datasets—including imaging, genomics, and clinical data—have led to innovative applications in the field. For instance, researchers funded by the National Cancer Institute (NCI) have developed AI models capable of predicting survival outcomes for patients with invasive, nonmetastatic breast cancer using digital pathology slide images. These models have demonstrated improved performance by combining histopathology and molecular data, surpassing traditional models that rely on a single data type.[206.1] Moreover, the Cancer Data Science Laboratory (CDSL) at NCI employs computational techniques to analyze and integrate laboratory and patient data from various "omics" research, thereby enhancing the understanding of cancer biology and identifying new therapeutic targets.[218.1] The establishment of platforms such as the NCI Genomic Data Commons (GDC) facilitates data sharing and provides analytical tools necessary for mining large datasets, which is crucial for advancing precision oncology practices.[218.1] However, the integration of these technologies presents significant challenges. The effective processing, analysis, and interpretation of large-scale multi-omics data remain critical hurdles that researchers must overcome to extract valuable insights.[217.1] Additionally, the increasing volume of data in cancer research necessitates the development of algorithm-based decision tools that can assist oncologists in making informed treatment decisions.[220.1] In parallel, the incorporation of Environmental, Social, and Governance (ESG) principles into cancer research is becoming increasingly important. This approach aims to create a sustainable and equitable cancer care system by addressing the interplay between environmental factors and cancer risk. Notably, 42% of cancer cases and 45% of cancer deaths are linked to modifiable risk factors, highlighting the need for comprehensive strategies that consider both individual behaviors and environmental influences.[216.1] Climate change, as an emerging public health threat, exacerbates cancer risk by increasing exposure to carcinogenic factors and disrupting healthcare delivery.[214.1] Thus, a multidisciplinary approach that integrates environmental policy with cancer research is essential for developing effective prevention strategies and addressing health disparities in cancer care.[215.1]In this section:
Cancer GenomicsNext-generation SequencingImplementation StrategiesBiomarkersBiological Therapies
References
[1] History of cancer - Wikipedia — History of cancer - Wikipedia History of cancer The history of cancer describes the development of the field of oncology and its role in the history of medicine. Cancer patient treatment and studies were restricted to individual physicians' practices until World War II when medical research centres discovered that there were large international differences in disease incidence. Main article: War on cancer ^ "The History of Cancer". ^ "The History of Cancer. DeVita V.T. and S.A. Rosenberg "Two Hundred Years of Cancer Research," New England Journal of Medicine (2012) 366#23 pp.2207–2214 pmid = 22646510 | pmc = 6293471 | doi = 10.1056/NEJMra1204479 "History of cancer, ancient and modern treatment methods." Cancer Science & Therapy 1.02 (2009) online Cancer Retrieved from "https://en.wikipedia.org/w/index.php?title=History_of_cancer&oldid=1279895947" History of cancer
[3] The History of Cancer Research: Introducing an AACR Centennial Series — A century is only a small segment in the timeline measuring the history of science through the ages, but for cancer research, the last 100 years overshadow all of the years that came before. Physicians have moved from being able to do very little to treat patients to achieving survival and cure rates no one believed possible. Just a few decades ago, young investigators and physicians were
[4] Understanding What Cancer Is: Ancient Times to Present — All About Cancer What Is Cancer? Cancer Glossary Cancer Care Explore All About Cancer All About Cancer Explore All About Cancer * Cancer Glossary Highlights of ACS Cancer Research ACS Research Team Bios* Early Cancer Detection Science All About Cancer What Is Cancer? Cancer Glossary Cancer Care Explore All About Cancer All About Cancer Explore All About Cancer * Cancer Glossary Highlights of ACS Cancer Research Cancer Help All About Cancer The History of Cancer What Is Cancer? * Cancer Glossary The History of Cancer Two Hundred Years of Cancer Research. Cancer. Cancer. Cancer. Cancer. The History of Cancer. Cancer Treatment Cancer If this was helpful, donate to help fund patient support services, research, and cancer content updates.
[5] The Biggest Cancer Research Breakthroughs in Recent Years — In October 2023, a potentially breakthrough vaccine for pancreatic cancer entered a Phase 2 clinical trial out of Memorial Sloan Kettering Cancer Center. The trial will evaluate whether the mRNA vaccine — which is customized for each of the approximately 260 enrolled patients at the center and sites around the world — prevents pancreatic
[6] Cancer Research Insights from the Latest Decade, 2010 to 2020 — All About Cancer What Is Cancer? All About Cancer All About Cancer What Is Cancer? All About Cancer For instance, ACS-funded researchers across the US have developed ways to quickly analyze the large amounts of data that result from gene sequencing, identify mutations in lung cancer genes, and helped find new treatments for lung cancer patients when the precision drug they were using stopped working. Over the last decade, ACS-funded researchers led the field in publishing studies on the benefits of early palliative care, finding that patients with metastatic non-small-cell lung cancer who received palliative care early in their treatment had big improvements in their quality of life and mood. Cancer If this was helpful, donate to help fund patient support services, research, and cancer content updates.
[8] The 2024 Impact Report of the Cancer Research Institute — CRI-funded researchers are addressing cancer’s complexity by identifying new targets such as tumor-specific neo-antigens, creating advanced genome-editing tools, and developing personalized cancer vaccines and cellular therapies. Beyond neo-antigen and cancer vaccines, CRI scientists are engaged in developing new strategies to identify the unique properties of tumors that can be exploited to develop personalized immunotherapies. Beyond supporting exceptional research, CRI funding provides training and career advancement opportunities, ensuring our scientists become world leaders in cancer immunotherapy. Upon receiving her CRI-Lloyd J Old STAR award, Dr. Merbl remarked “This grant will help us translate our scientific findings into innovative treatments, potentially offering new hope to cancer patients.” Building on CRI’s cutting-edge research in cancer immunotherapy, our clinical trials are advancing the fight against hard-to-treat cancers and pushing the boundaries to improve standard of care for patients.
[9] The Dawn of a New Era in Cancer Treatment - curetoday.com — New advancements in cancer treatment are reducing the need for radical surgeries, offering organ-sparing therapies and enhancing survivorship care and support for patients. ... However, a new era in cancer treatment is dawning, as we detail in this seasonal issue of CURE. Advancements in research and technology are allowing doctors to offer
[11] Exploring treatment options in cancer: tumor treatment strategies - Nature — The approval of T-VEC in 2015 and Delytact in 2021 for melanoma and malignant glioma, respectively, highlighted the resurgence of oncolytic viruses as a cancer treatment modality.19,20 The 2020 s have seen further advancements with the FDA approval of Sotorasib, the first small molecule inhibitor targeting specific KRAS gene mutations.21 In 2021, the National Comprehensive Cancer Network (NCCN) guidelines highlighted the combination of atezolizumab and bevacizumab as the preferred first-line treatment option for patients with hepatocellular carcinoma (HCC).22 This recommendation underscores the importance of immunotherapy and anti-angiogenic therapy in the frontline management of this aggressive form of cancer, reflecting the evolving landscape of cancer care and the continuous efforts to improve patient outcomes (Fig. 1).
[12] 11 new research advances from the past year - MD Anderson Cancer Center — Clinical Trials As part of our mission to eliminate cancer, MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers. The research, led by Florencia McAllister, M.D., professor of Gastrointestinal Medical Oncology and Genetics, and published in Cancer Cell, suggests a role for antibiotics or other interventions to maintain gut microbiome balance in trials with drugs targeting IL-17. Patients who received nivolumab had significantly prolonged event-free survival and a 42% reduction in risk of lung cancer progression, recurrence or death, according to research led by principal investigator Tina Cascone, M.D., Ph.D., associate professor of Thoracic/Head & Neck Medical Oncology.
[47] Two Hundred Years of Cancer Research | NEJM — In the mid-1970s, two landmark studies of adjuvant chemotherapy in breast cancer were published: one from the NSABP, which tested a single drug and was reported by Fisher and colleagues in 1975,15 and one from Italy, which tested a drug combination and was reported by Bonadonna et al. By 1991, thanks to the availability of multiple effective chemotherapeutic agents and hormone treatments, improved diagnostic tools for early diagnosis, and intelligently designed clinical trials, the rate of death from breast cancer began to fall, a trend that has continued.36 Early diagnosis and lumpectomy coupled with systemic therapy have greatly reduced the morbidity associated with breast-cancer treatment, with good cosmetic effects. Another paradigmatic change in cancer treatment occurred in 2006, when Druker et al.37 showed the efficacy of a drug (imatinib) that targeted the unique molecular abnormality in chronic myeloid leukemia.
[48] Exploring treatment options in cancer: tumor treatment strategies - Nature — The approval of T-VEC in 2015 and Delytact in 2021 for melanoma and malignant glioma, respectively, highlighted the resurgence of oncolytic viruses as a cancer treatment modality.19,20 The 2020 s have seen further advancements with the FDA approval of Sotorasib, the first small molecule inhibitor targeting specific KRAS gene mutations.21 In 2021, the National Comprehensive Cancer Network (NCCN) guidelines highlighted the combination of atezolizumab and bevacizumab as the preferred first-line treatment option for patients with hepatocellular carcinoma (HCC).22 This recommendation underscores the importance of immunotherapy and anti-angiogenic therapy in the frontline management of this aggressive form of cancer, reflecting the evolving landscape of cancer care and the continuous efforts to improve patient outcomes (Fig. 1).
[49] Cancer treatment and survivorship statistics, 2022 — The 5-year relative survival rate has increased from 75% for patients diagnosed in the mid-1970s to 90% for those diagnosed during 2011 through 2017, 11, 33 largely because of advances in hormonal treatments and earlier detection as a result of increased mammography screening prevalence. 34 The 5-year relative survival rate approaches 100% for
[52] A New Framework for Patient Engagement in Cancer Clinical Trials ... — We developed a structured process to engage patient advocates more effectively in the development of cancer clinical trials and piloted the process in four SWOG research committees, including implementation of a new Patient Advocate Executive Review Form that systematically captures patient advocates’ input at the concept stage. Our experience in engaging the leadership, researchers, protocol coordinators, and patient advocates at SWOG provides a framework for others interested in bringing the patient voice more directly into clinical trial conception and development. Based on the results of our pilot study of a structured process for patient engagement during the study concept development phase of research at SWOG, as well as the results from the Patient Advocate Engagement Experience Survey, SWOG leadership has implemented this new model for patient advocate engagement in research (Figure 3).
[53] Cancer patient advocacy: New opportunities for treatment advances — In the cancer arena, patient advocacy organizations have played critical roles in changing how the public views a particular kind of cancer by increasing public awareness of a specific cancer and demanding improvements in available treatments, access to these treatments, and specific and overall outcomes. Breast cancer provides a prime example.
[84] Why Is Cancer Research Important? - NCI - National Cancer Institute — Cancer research is the key to progress against cancer. There are four major types of research: basic, clinical, epidemiological, and translational. This infographic describes the differences between each type of research and how they can help drive progress. View and Print Infographic.
[85] What are the types of cancer research? | Masonic Cancer Center — The different types of cancer research are crucial team players in helping us develop whole-of-life methods for reducing the burden of cancer on Minnesotans. Basic research. The first level of research is called basic research, also known as laboratory research or bench science. Basic researchers study the cells, molecules, and genes that are
[86] PDF — • Cancer Research: Cancer Research Funding "Cancer research has always been among the most interdisciplinary of fields, mirroring the complexity of the many diseases it addresses." 1. Many classifications are used to describe different types of research. In this PIP Digest, we use the definitions of the
[87] How Do Researchers Translate Laboratory Findings to Clinical ... — Translating laboratory discoveries into clinical applications involves multiple steps. Initial findings in cellular or animal models are followed by clinical trials to evaluate the safety and efficacy of new treatments. Collaboration between laboratory scientists and clinicians is essential to bridge the gap between bench and bedside.
[88] Innovative laboratory techniques shaping cancer diagnosis and treatment ... — This review examines the evolving landscape of cancer detection, focusing on laboratory research breakthroughs and limitations in developing countries, while providing recommendations for advancing tumor diagnostics in resource-constrained environments. The search utilized keywords and phrases such as "cancer," "cancer diagnosis," "laboratory investigations," and "tumor research." Articles were selected based on their relevance to the study's aim of examining advancements in cancer diagnosis, with a particular focus on developing countries. Advancements in tumor diagnostic technologies, ranging from histopathology and molecular diagnostics to emerging tools such as single-cell technology, liquid biopsy, and artificial intelligence, have significantly enhanced cancer detection, classification, and treatment planning; however, their clinical impact in resource-limited settings remains constrained by high costs, technical complexity, and limited access.
[89] Translating lab discoveries to clinical trials in the age of ... — The pharmacogenomic groundwork laid in Yang's laboratory allows Karol to make great leaps in the clinic, particularly through individualized clinical trials such as RAVEN and SJALL23T. Exploring the rationale behind patient response to treatment means clinicians can make biologically informed decisions, maximizing positive patient outcomes.
[90] Global alliances in translational cancer research - Cell Press — Translating basic cancer biology into effective clinical therapies remains a major challenge due to differences in research models, communication gaps, and limited funding. This commentary underscores the transformative potential of international collaborations, which integrate diverse resources, multidisciplinary talent, and innovative trial designs to bridge the gap between laboratory
[91] Office of Translational Resources | Center for Cancer Research — The translation of basic research into therapeutics is a high priority for the CCR. The mission of the Office of Translational Resources (OTR) is to assist principal investigators (PIs) in rapidly translating advances in laboratory and clinical research into successful therapeutics and treatments for cancer. The OTR is available to offer advice and information to CCR PIs to facilitate
[93] Recent advances in the bench-to-bedside translation of cancer ... — Recent advances in the bench-to-bedside translation of cancer nanomedicines - ScienceDirect Recent advances in the bench-to-bedside translation of cancer nanomedicines Nanomedicines have shown great potential for revolutionizing cancer treatment by offering targeted and controlled drug delivery, reducing side effects, and improving patient outcomes. Accordingly, nanomedicines have been the focus of extensive research and development for clinical translation. Motivated by recent advances in the field, this review explores the current frontier of cancer nanomedicine. Future opportunities for cancer nanomedicines, including modifying the tumor microenvironment, integrating artificial intelligence and big data, and targeting new medical areas, are also discussed. This review underscores the potential of cancer nanomedicines to revolutionize treatment from a clinical standpoint. For all open access content, the Creative Commons licensing terms apply.
[94] CRISPR/Cas technologies for cancer drug discovery and treatment — Discoveries in basic biology can drive breakthroughs in applied cancer biology, and CRISPR gene editing has been fundamental to the development of new organoid and mouse knockout cancer models . For example, one study used CRISPR knockout to generate a human intestinal organoid model that recapitulated a classical mouse model of the sequential
[124] Top Cancer Treatment Advances at MSK in 2023 — Doctors at Memorial Sloan Kettering Cancer Center (MSK) pioneered advances in a variety of cancer treatment for patients in 2023. The results from many cutting-edge clinical trials this year are leading to promising new treatments for brain cancer, colorectal cancer, bladder cancer, endometrial cancer, and several different blood cancers. In addition, the Food and Drug Administration (FDA) approved seven drugs in 2023 based on clinical trials in which MSK played a pivotal role. “We are living in a transformative age for cancer care, where advances in the lab are moving into the clinic faster than ever before,” says MSK President and CEO Selwyn M. Vickers, MD, FACS.
[128] Epigenetic alterations and mechanisms that drive resistance to targeted ... — A worthy step in this direction is the TRACERx project, which integrates several technologies to study evolution of different cancer types under therapeutic intervention (78 - 81). These studies are expected to lay the foundation for providing long-term care for cancer patients, even when first-line therapies fail, and drug resistance emerge.
[129] How TRACERx is helping us predict lung cancer's next move — Of these, around 80 to 85% are NSCLC. Since 2014, TRACERx has been collecting comprehensive genomic and clinical data from people with NSCLC, from their point of diagnosis throughout their treatment, to unpick the complexities of lung cancer and aid the design of new, targeted lung cancer treatments.
[137] A comprehensive overview on antibody-drug conjugates: from the ... — Unlike conventional chemotherapeutic drug-based therapies, that are mainly associated with modest specificity and therapeutic benefit, the three key components that form an ADC (a monoclonal antibody bound to a cytotoxic drug via a chemical linker moiety) achieve remarkable improvement in terms of targeted killing of cancer cells and, while sparing healthy tissues, a reduction in systemic side effects caused by off-tumor toxicity. Beginning with the first ADC, which was approved by the Food and Drug Administration (FDA) in 2000 (Norsworthy et al., 2018), and given the ever-evolving technology of mAbs, linkers, and payloads, by April 2023 13 different ADCs have been FDA-approved for clinical use for both solid and hematologic malignancies, setting the stage for a new era of targeted cancer therapy (Dumontet et al., 2023).
[144] FDA Approvals - Cancer Currents Blog - NCI — People with advanced endometrial cancer now have new FDA-approved treatment options: pembrolizumab and durvalumab, paired with chemotherapy, for tumors with a genetic change called mismatch repair deficiency.
[165] A view on drug resistance in cancer - Nature — Advertisement A view on drug resistance in cancer Nature volume 575, pages 299–309 (2019)Cite this article 129k Accesses 1133 Citations 241 Altmetric Metrics details Subjects Abstract The problem of resistance to therapy in cancer is multifaceted. Here we take a reductionist approach to define and separate the key determinants of drug resistance, which include tumour burden and growth kinetics; tumour heterogeneity; physical barriers; the immune system and the microenvironment; undruggable cancer drivers; and the many consequences of applying therapeutic pressures. We propose four general solutions to drug resistance that are based on earlier detection of tumours permitting cancer interception; adaptive monitoring during therapy; the addition of novel drugs and improved pharmacological principles that result in deeper responses; and the identification of cancer cell dependencies by high-throughput synthetic lethality screens, integration of clinico-genomic data and computational modelling. Main Drug resistance continues to be the principal limiting factor to achieving cures in patients with cancer. Here we attempt to present a framework for conceptualizing drug resistance in cancer by enumerating the basic determinants of resistance and considering their implications for the development of successful therapeutic strategies.
[166] A protracted war against cancer drug resistance | Cancer Cell ... — A comprehensive understanding of the underlying mechanisms contributing to the complex story of tumor progression and drug resistance will help facilitate the development of effective approaches that are aimed at preventing the clonal selection of drug-tolerant cancerous cells and maximizing patient benefits. This so-called “tumor evolution” describes the presence of multiple divergent cancer cell subpopulations in the same tumor or patient, promoting primary/metastatic lesions and cancer relapse as well as drug resistance after therapeutic failure . Differences in TME are another form of tumor heterogeneity contributing cancer drug resistance by preventing immune clearance of malignant cells, hindering drug absorption and stimulating paracrine growth factors to signal cancer cell growth, etc .
[167] Why Do Cancer Treatments Stop Working? - NCI - National Cancer Institute — One combination treatment approach is to "co-administer drugs that work by different molecular mechanisms," Bissan Al-Lazikani, Ph.D., of Cancer Research UK and her colleagues wrote in Nature Biotechnology, "thereby increasing tumor cell killing while reducing the likelihood of drug resistance and minimizing overlapping toxicity.". Another approach is to treat patients with drugs that block
[181] A role for cancer stem cells in therapy resistance: cellular and ... — In this review we describe the mechanisms of CSC-related therapy resistance including drug efflux by ABC transporters, activation of aldehyde dehydrogenase and developmental pathways, enhanced DNA damage response, autophagy and microenvironmental conditions, and discuss possible therapeutic strategies for improving cancer treatment.
[189] Recent Advances in Artificial Intelligence to Improve Immunotherapy and ... — To achieve the required levels of diagnostic and therapeutic precision, it is necessary to integrate data from different sources and simulation platforms. Today, artificial intelligence (AI), machine learning (ML), and predictive computer models are more efficient at guiding decisions regarding better therapies and medical procedures.
[190] (PDF) The Significance of Artificial Intelligence and Machine Learning ... — Artificial intelligence (AI) and machine learning (ML) have emerged as transformative tools for identifying new immunotherapy targets by analyzing vast datasets from genomics, proteomics, and
[192] Cancer Care Disparities: Overcoming Barriers to Cancer Control in Low ... — Cancer is a leading cause of morbidity and mortality worldwide. The majority of new patients with cancer and deaths now occur in low- and middle-income countries (LMICs). 1 LMICs account for 57% of new patients with cancer and 65% of deaths. 1,2 However, profound health system challenges impede implementing comprehensive cancer services, including prevention, screening, diagnosis, treatment
[193] Eliminate Cancer Health Disparities - National Cancer Plan — Eliminate Cancer Health Disparities - National Cancer Plan Eliminate Cancer Health Disparities - National Cancer Plan Prevent Cancer Eliminate Cancer Health Disparities Eliminate Cancer Health Disparities - National Cancer Plan Goal: Disparities in cancer risk factors, incidence, treatment side effects, and mortality are eliminated through equitable access to prevention, screening, treatment, and survivorship care. The reasons for cancer disparities are complex and include both biological and societal factors that impact a person’s health. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Eliminate Cancer Health Disparities - National Cancer Plan was originally published by the National Cancer Institute.” NCI Cancer Research 1-800-4-CANCER
[195] Reducing Cancer Disparities through Community Engagement in Policy ... — Along with other partners in the public health system, community- based organizations such as local cancer councils can play valuable roles in developing policies that are responsive to community needs and in mobilizing resources to support policy adoption and implementation. Community-based organizations (CBOs) are a popular choice for addressing public health problems in communities where other kinds of approaches have failed.7– 16 Community-based organizations are being recognized as a key mechanism for intervention-related activities from smoking to teen pregnancy to underage drinking and driving to cancer prevention and screening.17,18 In its 2002 report, The Future of the Public’s Health, the Institute of Medicine recommended governmental public health agencies provide direct support for community health-improvement initiatives by assessing community needs, providing technical assistance, and developing solutions that improve health status. Community engagement through local cancer councils may inform and improve the policy development processes within public health systems.
[206] Artificial Intelligence (AI) and Cancer — In recent years, advances in three areas—methods and algorithms for training AI models, computer hardware needed to train these models, and access to large volumes of cancer data such as imaging, genomics, and clinical data—have converged, leading to promising new applications of AI in cancer research. NCI-funded researchers have developed an AI model that can predict survival outcomes for patients with invasive, nonmetastatic breast cancer using digital pathology slide images. For example, NCI-funded researchers have developed AI methods to combine histopathology data and molecular data to predict outcomes from patients with brain cancer that perform better than models using one data type. NCI is committed to supporting research aimed at addressing these challenges and advancing the development of AI methods that will accelerate the effort to end cancer as we know it.
[210] Personalized immunotherapy in cancer precision medicine — Personalized immunotherapy in cancer precision medicine - PubMed With the significant advances in cancer genomics using next-generation sequencing technologies, genomic and molecular profiling-based precision medicine is used as a part of routine clinical test for guiding and selecting the most appropriate treatments for individual cancer patients. Although many molecular-targeted therapies for a number of actionable genomic alterations have been developed, the clinical application of such information is still limited to a small proportion of cancer patients. Cancer immunotherapies, which target neoantigens, could lead to a precise treatment for cancer patients, despite the challenge in accurately predicting neoantigens that can induce cytotoxic T cells in individual patients. Precise prediction of neoantigens should accelerate the development of personalized immunotherapy including cancer vaccines and T-cell receptor-engineered T-cell therapy for a broader range of cancer patients. doi: 10.3390/cancers16193254.
[211] Revolutionizing cancer treatment: the rise of personalized ... — It acknowledges the challenges, including drug resistance and the need for high specificity in certain therapies, while also highlighting the effectiveness of cancer vaccines, modified T-cells, and oncolytic viruses. There are different types of biological therapies for cancer and they include: cancer vaccines, angiogenesis inhibitors, adoptive cell transfer, monoclonal antibodies, immune checkpoint modulators, targeted drug therapy, chimeric antigen receptor (CAR) T-cell therapy, targeted drug therapy and chemotherapy, cytokine therapy, Bacillus Calmette-Guerin therapy, gene therapy, immunoconjugates and oncolytic virus therapy. In this review, we have discussed various biological therapies and their effectiveness in targeting different types of cancers, with a focus on the potential of monoclonal antibodies and adoptive cell transfer in personalized medicine.
[214] Climate Change and Cancer — Climate change is an environmental and public health threat with implications across the cancer control continuum. Climate change-fueled events increase exposures to cancer risk factors, reduce food access and nutritional quality, impede health behaviors, and disrupt cancer care delivery. ... Expand and enhance research to understand and
[215] An Action Plan for Environmentally Sustainable Cancer Care — Determining the climate effects of oncology care would require a systematic assessment of GHG emissions from cancer research and practice. The term given to these analyses is the life-cycle assessment, 5 in which a "life-cycle" indicates all activities performed across a process or product, from raw materials extraction until disposal.
[216] Behavioural and structural interventions in cancer prevention: towards ... — Interventions in individual lifestyles have often been viewed as the main component of cancer prevention strategies. However, environmental factors may facilitate or impede healthy behaviours. The behavioural‐structural dichotomy of cancer prevention can only be resolved by incorporating the 'Health in All Policies' perspective at
[217] Big data and artificial intelligence in cancer research — Big data and artificial intelligence in cancer research - ScienceDirect Big data and artificial intelligence in cancer research We provide a comprehensive overview of advances in the application of big data and AI technologies in cancer research. We propose a machine learning based intelligent service platform, designed to integrate cancer big data and employ AI algorithms for personalized health management. We provide a comprehensive overview of the current state of the art in big data and computational analysis, highlighting key applications, challenges, and future opportunities in cancer research. The integration of big data and AI in cancer research offers unprecedented discovery and application in precision oncology practices. However, how to effectively process, analyze, integrate, and interpret these large-scale multi-omics data to extract valuable information remains a major challenge for current cancer research.
[218] Bioinformatics, Big Data, and Cancer - NCI — The Cancer Data Science Laboratory (CDSL), in NCI's Center for Cancer Research, develops and uses computational approaches to analyze and integrate laboratory and patient data from cancer genomics and other "omics" research. Data from these initiatives and other NCI-supported studies have helped researchers better understand the biology of different cancers and identify potential new targets for therapies. NCI's Office of Data Sharing (ODS) coordinates data sharing policies across NCI and the cancer research community. The NCI Genomic Data Commons (GDC) provides a single source for data from NCI-funded initiatives and cancer research projects, as well as the analytical tools needed to mine them. Sign up for email updates
[220] Translating "Big Data" in Oncology for Clinical Benefit: Progress or ... — Analysis of the ever-increasing data explosion in cancer research and care represents perhaps the field's biggest challenge in providing the right algorithm-based decision tools to oncologists.